Status:
TERMINATED
Effect of ESDM and PCIT-A in Autism Spectrum Disorder
Lead Sponsor:
Bruno Rhiner
Collaborating Sponsors:
West Virginia University
University of Arkansas
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
24-59 years
Phase:
NA
Brief Summary
Children with ASD often show disruptive behaviors. However, interventions that were specifically designed to improve these symptoms have not been sufficiently investigated, especially in children with...
Detailed Description
Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder with recognizable symptoms often beginning between one and two years of age and an estimated prevalence of about 0.6%. Both so...
Eligibility Criteria
Inclusion
- ASD level 1 to 3
- Time commitment of at least one parent (including homework and traveling time)
- Willingness of one parent to be the study informant over the whole study period
Exclusion
- Insufficient German language skills of both parents to participate in the intervention
- Severe hearing or visual impairment
- Attention deficit hyperactivity disorder
- Epilepsy
- Rett syndrome
- Other rare, severe neurological disorders that interfere with therapy
Key Trial Info
Start Date :
January 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04722783
Start Date
January 14 2021
End Date
October 21 2024
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric Services of Thurgovia
Münsterlingen, Thurgau, Switzerland, 8596